Sanofi VaxRabeo has secured European Commission approval as a next-generation rabies vaccine for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) in all age groups. Sanofi announced the decision from Paris on November 19, 2026. The authorisation covers VaxRabeo (rabies virus inactivated strain Wistar) and is the first marketing authorisation approval for the product.
The approval follows a positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use on September 17, 2026. For public health teams and vaccine buyers, the Sanofi VaxRabeo decision adds a newer option alongside Sanofi’s current rabies vaccines, Verorab and Imovax Rabies. Readers tracking the sector can also follow our vaccine news coverage for related regulatory updates.
Thomas Triomphe, Head of Vaccines at Sanofi, called the approval a proud milestone that reflects the company’s commitment to rabies protection, built on five decades of expertise and innovation. He said “Death from rabies should be prevented at all costs,” adding that the vaccine brings a next-generation option to healthcare systems and patients.
Sanofi VaxRabeo Technology: Vero-Cell Manufacturing, Shelf Life and Thermostability
Sanofi VaxRabeo is manufactured using state-of-the-art Vero-cell technology. Sanofi says the vaccine is formulated to minimize the risk of allergic reactions and offers a longer shelf life than the company’s current rabies vaccines, along with improved thermostability. The table below summarizes the product profile exactly as disclosed by Sanofi.
| Attribute | Detail disclosed by Sanofi |
|---|---|
| Product name | VaxRabeo (rabies virus inactivated strain Wistar) |
| Developer | Sanofi |
| Approval body | European Commission |
| Indication | Pre-exposure and post-exposure prophylaxis against rabies |
| Age groups | All age groups |
| Manufacturing platform | Vero-cell technology |
| Shelf life | 60 months (five years) |
| Stability before reconstitution | Up to 27°C for 96 hours |
| Viral strain | Same strain as Verorab and Imovax Rabies |
The shelf-life data are among the most practical details in the announcement. VaxRabeo has a 60-month shelf life and maintains stability at temperatures up to 27°C for 96 hours before reconstitution. Those figures matter for clinics, travel health centres and national programmes that must store and move vaccines without interruption.
VaxRabeo shares the same viral strain as Verorab and Imovax Rabies, which Sanofi says have demonstrated safety and efficacy over more than five decades. It is indicated for PrEP and PEP in every age group and supports flexible schedules, including a reduced WHO-recommended two-dose PrEP regimen and a four-dose PEP regimen for unvaccinated individuals, given with or without rabies immunoglobulin.
Sanofi VaxRabeo Clinical Programme: PrEP and PEP Results
The European approval of Sanofi VaxRabeo rests on a comprehensive clinical programme. Sanofi compared the vaccine with its current standard-of-care vaccines, Verorab and Imovax Rabies, in both PrEP and PEP settings. The studies covered all age groups and WHO-recommended schedules, which gives regulators and clinicians a like-for-like view of performance.
In PrEP studies, two-dose and three-dose regimens of Sanofi VaxRabeo achieved protective antibody levels comparable to those of Verorab and Imovax Rabies in both adults and children. Booster doses given 12 months or 24 to 36 months after the last PrEP dose showed high boostability, which Sanofi says supports the lasting immunogenicity of the vaccine.
In PEP studies, the vaccine showed an immunogenicity profile similar to Sanofi’s current standard-of-care vaccines, with or without rabies immunoglobulins. Sanofi reports that 100% of participants achieved protective antibody levels intramuscularly. Across all studies, the safety profile was in line with existing vaccines, the vaccine was well tolerated, and no significant safety concerns were identified.
| Setting | Comparator | Reported outcome |
|---|---|---|
| PrEP (two-dose and three-dose regimens) | Verorab, Imovax Rabies | Comparable protective antibody levels in adults and children |
| PrEP booster (12 or 24-36 months) | Not disclosed | High boostability |
| PEP (with or without immunoglobulins) | Verorab, Imovax Rabies | Similar immunogenicity profile |
| PEP (intramuscular) | Not disclosed | 100% of participants reached protective antibody levels |
| Safety (all studies) | Existing vaccines | In line with existing vaccines, no significant safety concerns |
Why the Sanofi VaxRabeo Approval Matters for Global Rabies Prevention
Rabies is a viral zoonotic disease present in 150 countries, and the World Health Organization estimates it causes approximately 59,000 deaths worldwide each year. No treatment exists once clinical symptoms appear, and the disease is almost always fatal. It is preventable only through vaccination, combined with immunoglobulins in post-exposure prophylaxis. WHO also estimates that approximately 29 million people receive post-exposure vaccination annually. See the WHO rabies fact sheet for global context.
Transmission occurs mainly through the saliva of infected animals, with dogs responsible for most human cases through bites, scratches and contact with broken skin. Cats, bats, foxes, raccoons, skunks, jackals and mongooses can also transmit the virus. The burden falls heavily on children, because 40% of people bitten by suspect rabid animals are under 15 years of age. Preventable deaths continue, particularly in Asia and Africa.
Travel medicine is another use case highlighted in the release. Potential rabies exposure occurs in approximately 0.4% of travellers per month of stay in endemic regions, which makes pre-travel vaccination an important consideration. With a PrEP indication for all ages, Sanofi VaxRabeo gives European prescribers another authorised choice for travellers and at-risk groups. Our travel and infectious disease reports track similar developments.
| Rabies metric | Figure reported by Sanofi (citing WHO where stated) |
|---|---|
| Countries with rabies | 150 |
| Estimated annual deaths worldwide | Approximately 59,000 |
| People receiving post-exposure vaccination each year | Approximately 29 million |
| Share of bite victims under 15 years | 40% |
| Traveller exposure risk | Approximately 0.4% per month of stay |
| Main source of human cases | Dogs |
Sanofi VaxRabeo Regulatory Timeline, Sources and Forward-Looking Statements
The regulatory path for Sanofi VaxRabeo moved from a CHMP positive opinion on September 17, 2026 to European Commission approval announced on November 19, 2026. Sanofi did not disclose a European launch date, pricing, reimbursement plans, manufacturing capacity or filings in other regions. Those items are labeled “Not disclosed” in the table below rather than estimated.
| Milestone | Date or status |
|---|---|
| CHMP positive opinion | September 17, 2026 |
| European Commission approval | Announced November 19, 2026 |
| Launch timing in the EU | Not disclosed |
| Pricing and reimbursement | Not disclosed |
| Approvals outside the EU | Not disclosed |




